|
|
Upfront Briefing
Novo spent a day in London explaining life after semaglutide, pinned a $23B 2035 pipeline-sales ambition on it, and got its worst Copenhagen session since February for the trouble. Grail had the opposite kind of Monday: FDA staff papers left very little to argue about ahead of Wednesday's Galleri panel. Also in the mix: a FOIA'd Pfizer contract shows HHS taking a cut of higher foreign prices, Bayer offloads Stivarga to Grünenthal for up to €375M, and IMS opens in Glasgow tomorrow.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
7,764.7 |
1.5% |
13.4% |
| Nasdaq 100 |
30,482.4 |
2.8% |
20.9% |
| Russell 2000 |
2,875.4 |
0.5% |
15.9% |
| Healthcare (XLV) |
169.0 |
0.4% |
9.2% |
| Biotech (XBI) |
158.2 |
1.0% |
29.8% |
| Nasdaq Biotech (NBI) |
7,047.4 |
1.1% |
23.5% |
| Clinical Trials (BBC) |
48.7 |
0.2% |
29.4% |
|
- Biotech trailed the broad rally: XBI rose 1.0% and NBI 1.1% against the S&P 500's 1.5%, while XLV added 0.4%. Single-name moves ran both ways, with Grail up 34% on FDA briefing papers posted before the open and Novo's ADR down about 8% after its Capital Markets Day.
- Chips led the tape as the Nasdaq 100 jumped 2.8%, with Brent slipping back toward $100 and the 10-year easing to 4.95%, and the AI trade bid ahead of Thursday's Trump–Xi summit at the White House.
- Market data: U.S. cash close Monday, 21 September 2026.
The Big 3
|
1
|
Novo sets a $23B 2035 goal and loses 7.7% for it |
- At its London Capital Markets Day, Novo targeted more than DKK150B (~$23B) of risk-adjusted pipeline sales in 2035 and more than five multi-blockbuster launches by 2030; Copenhagen shares closed down 7.7%.
- Why it matters: Novo put a number on life after semaglutide: more than DKK150B (~$23B) of risk-adjusted pipeline sales in 2035, current assets included, plus 2026–2030 revenue growth pitched only to match a peer set that includes Lilly, Merck and AstraZeneca. Matching peers is the concession. Management called semaglutide's loss of exclusivity early next decade the elephant in the room, and nothing in the plan bridges it before then. Copenhagen closed down 7.7%, the worst day since February, and the ADR was still off about 8% late in the US session. The Kallyope and Orbis deals of the past week look like early-stage breadth, not a replacement franchise, so the call for a larger acquisition gets louder. Next hard catalyst: the US CagriSema obesity decision, expected around year-end.
- Source: Fierce Biotech
- More: CNBC; BioPharma Dive
|
|
2
|
Grail jumps 34% as FDA staff clear the way to Galleri's panel |
- FDA briefing documents for Wednesday's (23 Sep) advisory panel on Galleri, Grail's multi-cancer blood test, raised no outstanding questions on analytical performance, study design or primary safety; GRAL rose 34%.
- Why it matters: FDA staff left the panel no outstanding questions on Galleri's analytical performance, study design or primary safety analyses, and GRAL closed up 34% at about $108 from $80.77, its best day since February 2025. The one open question is narrower but real: reviewers asked whether the evidence supports calling Galleri an early detection test, which runs straight back to February, when NHS-Galleri failed to significantly cut late-stage diagnoses. The PMA leans instead on PATHFINDER 2's 25,490 participants and the first NHS-Galleri screening round of more than 70,000. A favourable vote matters mainly for Medicare coverage, which approval is expected to unlock. After a one-day re-rating, a split vote on labelling is now the downside case. Grail expects the FDA decision in the first part of 2027.
- Source: STAT
- More: BioWorld
|
| 3 | Pfizer's MFN contract hands HHS a cut of higher foreign prices |
- Pfizer and Lilly MFN contracts released by Public Citizen under FOIA show Pfizer sharing a portion of net increased revenue from higher ex-US prices with HHS; rates and covered products are redacted.
- Why it matters: The contract Public Citizen obtained through a FOIA suit shows Pfizer ceding to HHS a share of the net incremental revenue it earns from raising prices abroad, on marketed drugs, from 1 January 2026 to 20 January 2029. The rate and the product list are redacted, the redactions leave it unclear whether Lilly signed the same clause, and more than two dozen other MFN contracts stay confidential. That goes to the one lever pharma has sold as its MFN offset. If HHS takes a cut of every foreign price rise, ex-US pricing becomes a lower-quality earnings source for all 26 signatories until the rate is known. It also binds pricing tighter to trade policy, where the UK deal already commits the NHS to 25% higher medicine spending.
- Source: Endpoints
- More: Bloomberg; Fierce Pharma
|
Everything Else that broke
- Bayer is selling Stivarga to Grünenthal for up to €375M (~$431M) ahead of exclusivity loss in 2029 (EU) and 2030 (US); close expected by end-2026 or early 2027. — Fierce Pharma
- J&J's Caplyta cut YMRS scores 4.8 points more than placebo at week 3 in its first phase 3 in bipolar I mania, with response rates of 45.8% vs 20.9%. — Fierce Pharma
- The EC approved NewAmsterdam and Menarini's Ubeslo and Evlarco, the first approval for obicetrapib anywhere. — GlobeNewswire
- FDA approved IntraBio's Aqneursa for ataxia-telangiectasia. — Endpoints
- The White House plans to put NIH grant decisions under political control, according to reports. — Fierce Biotech
- The Pentagon is defending WuXi AppTec's Chinese military-company designation after a temporary court block. — Endpoints
- Trump called for some routine childhood vaccines to be split into five smaller doses. — Fierce Pharma
Deal Flow
| BioBucks 2026 Deal Trackers • Updated weekly ⬇️
|
M&A / BD&L
- Grünenthal / Bayer — Stivarga (regorafenib), up to €375M (~$431M); Grünenthal guides to up to ~€100M 2027 EBITDA contribution. — Fierce Pharma
- PTC completed its acquisition of BLA-stage Fabry gene therapy ST-920, with filing completion expected in Q4 2026. — PR
- Iambic signed an R&D partnership with AbbVie alongside the release of its next-gen Enchant model. — Endpoints
VC / Private Financings
- No notable VC or private financings in the last 24 hours.
IPOs / Follow-Ons
- ADARx (ADRX) set IPO terms at 21.875M shares for $15–17 (~$350M at midpoint, ~$1.74B valuation), with AbbVie buying up to $100M concurrently for ~4.9%; onvuzosiran is in Ph3 STOP-HAE. TRexBio and Retension also filed. — Endpoints
Academic Corner - Review of vaccines for cancer. — JAMA
|
One pipeline plan, one panel preview, one leaked contract. Back tomorrow. — BioBucks Team
|
|
|
